Prophylaxis of invasive mycoses in solid organ transplantation

Current Infectious Disease Reports

Volumn 11, Issue 6, 2009, Pages 427-434

  Alexander, Barbara D ^a   Radack, Kyle P ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; LYMPHOCYTE ANTIBODY; MICAFUNGIN; MIDAZOLAM; OKT 3; PHENYTOIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAPAMYCIN; RIFABUTIN; TACROLIMUS; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; BRAIN DISEASE; BRONCHOSPASM; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC VALUE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INTESTINE TRANSPLANTATION; INVASIVE CANDIDIASIS; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; MYCOSIS; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; POSTOPERATIVE PERIOD; REVIEW; RISK FACTOR; SOMNOLENCE; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

EID: 70449490649     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0062-y     Document Type: Review

References (65)

1. C.V. Paya 1993 Fungal infections in solid-organ transplantation Clin Infect Dis 16 677 688 1:STN:280:DyaK3s3otlGmtA%3D%3D 8507760
2. K.C. Abbott I. Hypolite R.K. Poropatich, et al. 2001 Hospitalizations for fungal infections after renal transplantation in the United States Transpl Infect Dis 3 203 211 10.1034/j.1399-3062.2001.30404.x 1:STN:280: DC%2BD387htVOnsQ%3D%3D 11844152 (Pubitemid 34051921)
3. N. Singh R.K. Avery P. Munoz, et al. 2003 Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients Clin Infect Dis 36 46 52 10.1086/345441 12491201 (Pubitemid 36099096)
4. P. Martin-Davila J. Fortun R. Lopez-Velez, et al. 2008 Transmission of tropical and geographically restricted infections during solid-organ transplantation Clin Microbiol Rev 21 60 96 10.1128/CMR.00021-07 1:STN:280:DC%2BD1c%2FkvFeltw%3D%3D 18202437 (Pubitemid 351160010)
5. Y. Raviv M.R. Kramer A. Amital, et al. 2007 Outbreak of aspergillosis infections among lung transplant recipients Transpl Int 20 135 140 10.1111/j.1432-2277.2006.00411.x 17239021 (Pubitemid 46121991)
6. I. Stelzmueller C. Lass-Floerl C. Geltner, et al. 2008 Zygomycosis and other rare filamentous fungal infections in solid organ transplant recipients Transpl Int 21 534 546 10.1111/j.1432-2277.2008.00657.x 18363572 (Pubitemid 351600072)
7. J. Gavalda O. Len J.R. San, et al. 2005 Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study Clin Infect Dis 41 52 59 10.1086/430602 1:STN:280:DC%2BD2M3ptVWnsA%3D%3D 15937763 (Pubitemid 40863744)
8. F.Y. Chang N. Singh T. Gayowski, et al. 2000 Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoietin Transplantation 69 70 75 10.1097/00007890-200001150- 00014 1:STN:280:DC%2BD3c7hslWjug%3D%3D 10653383 (Pubitemid 30062611)
9. A.K. Zaas G. Liao J.W. Chien, et al. 2008 Plasminogen alleles influence susceptibility to invasive aspergillosis PLoS Genet 4 e1000101 10.1371/journal.pgen.1000101 18566672 (Pubitemid 351914806)
10. M.J. George D.R. Snydman B.G. Werner, et al. 1997 The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland Am J Med 103 106 113 10.1016/S0002-9343(97)80021-6 1:STN:280:DyaK2svhvVyitQ%3D%3D 9274893 (Pubitemid 27352114)
11. J.A. Wagner H. Ross S. Hunt, et al. 1995 Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation Transplantation 60 1473 1477 10.1097/00007890-199560120-00018 1:CAS:528:DyaK28Xht1ahs7Y%3D 8545877
12. A.C. Kalil J. Levitsky E. Lyden, et al. 2005 Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients Ann Intern Med 143 870 880 16365468
13. N.C. Issa J.A. Fishman 2009 Infectious complications of antilymphocyte therapies in solid organ transplantation Clin Infect Dis 48 772 786 10.1086/597089 1:CAS:528:DC%2BD1MXktVyrsbk%3D 19207081
14. N.J. Mueller 2008 New immunosuppressive strategies and the risk of infection Transpl Infect Dis 10 379 384 10.1111/j.1399-3062.2008.00346.x 1:STN:280:DC%2BD1cjosFCnsw%3D%3D 18811628
15. A.Y. Peleg S. Husain E.J. Kwak, et al. 2007 Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody Clin Infect Dis 44 204 212 10.1086/510388 1:CAS:528: DC%2BD2sXhsVKmsr4%3D 17173218 (Pubitemid 46079982)
16. H.P. Tan J. Donaldson A. Basu, et al. 2009 Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up Am J Transplant 9 355 366 10.1111/j.1600-6143.2008.02492.x 1:CAS:528:DC%2BD1MXjtFGns7w%3D 19120078
17. S. Hadley M.H. Samore W.D. Lewis, et al. 1995 Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression Transplantation 59 851 859 10.1097/00007890-199503270-00009 1:STN:280: DyaK2M3hs1Wisw%3D%3D 7535482
18. L.A. Collins M.H. Samore M.S. Roberts, et al. 1994 Risk factors for invasive fungal infections complicating orthotopic liver transplantation J Infect Dis 170 644 652 1:STN:280:DyaK2czlvVGjsg%3D%3D 8077723
19. P.G. Pappas D. Andes M. Schuster, et al. 2006 Invasive fungal infections in low-risk liver transplant recipients: a multicenter prospective observational study Am J Transplant 6 386 391 10.1111/j.1600-6143.2005.01176.x 1:STN:280:DC%2BD28%2FjvVChsQ%3D%3D 16426325 (Pubitemid 43382176)
20. S. Hadley C. Huckabee P.G. Pappas, et al. 2009 Outcomes of antifungal prophylaxis in high-risk liver transplant recipients Transpl Infect Dis 11 40 48 10.1111/j.1399-3062.2008.00361.x 1:STN:280:DC%2BD1M%2FosVOjsQ%3D%3D 19144094
21. M. Osawa Y. Ito T. Hirai, et al. 2007 Risk factors for invasive aspergillosis in living donor liver transplant recipients Liver Transpl 13 566 570 10.1002/lt.21099 17394155 (Pubitemid 46605860)
22. N. Singh 2000 Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy Clin Infect Dis 31 545 553 10.1086/313943 1:CAS:528:DC%2BD3cXnsVKqu74%3D 10987719 (Pubitemid 32289589)
23. F.P. Silveira E.J. Kwak D.L. Paterson, et al. 2008 Post-transplant colonization with non-Aspergillus molds and risk of development of invasive fungal disease in lung transplant recipients J Heart Lung Transplant 27 850 855 10.1016/j.healun.2008.05.021 18656797 (Pubitemid 352020631)
24. R. Kowalski D. Post M.C. Schneider, et al. 2003 Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management Clin Transplant 17 77 88 10.1034/j.1399-0012.2003.00013.x 12709071 (Pubitemid 36833776)
25. S. Husain K. Raza J.M. Pilewski, et al. 2009 Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection Transplantation 87 1852 1857 10.1097/TP.0b013e3181a75ad2 1:CAS:528:DC%2BD1MXnsFyht7s%3D 19543064
26. P. Munoz C. Rodriguez E. Bouza, et al. 2004 Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis Am J Transplant 4 636 643 10.1111/j.1600-6143.2004.00390.x 1:CAS:528:DC%2BD2cXjs1OqsLc%3D 15023157 (Pubitemid 38523587)
27. J.M. O'Neill G.E. Schutze M.J. Heulitt, et al. 2001 Nosocomial infections during extracorporeal membrane oxygenation Intensive Care Med 27 1247 1253 10.1007/s001340101029 11511935 (Pubitemid 32771332)
28. L. Albano S. Bretagne M.F. Mamzer-Bruneel, et al. 2009 Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France Clin Infect Dis 48 194 202 10.1086/595688 19090753
29. E. Benedetti A.C. Gruessner C. Troppmann, et al. 1996 Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome J Am Coll Surg 183 307 316 1:STN:280:DyaK2s%2FgtVWitw%3D%3D 8843258
30. B.D. Alexander W.A. Schell J.L. Miller, et al. 2005 Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole Transplantation 80 868 871 10.1097/01.tp.0000173771.47698.7b 16210978 (Pubitemid 41443773)
31. N. Kung N. Fisher B. Gunson, et al. 1995 Fluconazole prophylaxis for high-risk liver transplant recipients Lancet 345 1234 1235 10.1016/S0140- 6736(95)92014-5 1:STN:280:DyaK2M3lslKrsg%3D%3D 7739317
32. D.P. Kontoyiannis 2002 Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis Clin Infect Dis 34 1281 1283 10.1086/339946 11941561 (Pubitemid 34450682)
33. M.D. Sharpe C. Ghent D. Grant, et al. 2003 Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study Transplantation 76 977 983 10.1097/01.TP.0000085653.11565.52 1:CAS:528:DC%2BD3sXnsFanu7g%3D 14508365 (Pubitemid 37186031)
34. D.J. Winston R.W. Busuttil 2002 Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients Transplantation 74 688 695 10.1097/00007890-200209150-00017 1:CAS:528:DC%2BD38XnsVarsLk%3D 12352887
35. D. Shitrit J.E. Ollech A. Ollech, et al. 2005 Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction J Heart Lung Transplant 24 2148 2152 10.1016/j.healun.2005.05.003 16364864 (Pubitemid 41814739)
36. T.F. Patterson J. Peters S.M. Levine, et al. 1996 Systemic availability of itraconazole in lung transplantation Antimicrob Agents Chemother 40 2217 2220 1:CAS:528:DyaK28XlsVCgtrw%3D 8878612
37. VFend IV, tablets, oral suspension [package insert]. New York: Pfizer, Inc.; 2008.
38. S. Husain D.L. Paterson S. Studer, et al. 2006 Voriconazole prophylaxis in lung transplant recipients Am J Transplant 6 3008 3016 10.1111/j.1600-6143. 2006.01548.x 1:CAS:528:DC%2BD2sXhtVGhsw%3D%3D 17062003 (Pubitemid 44777932)
39. V. Boussaud N. Daudet E.M. Billaud, et al. 2008 Neuromuscular painful disorders: a rare side effect of voriconazole in lung transplant patients under tacrolimus J Heart Lung Transplant 27 229 232 10.1016/j.healun.2007.09.022 1:STN:280:DC%2BD1c7gvVyjtA%3D%3D 18267232 (Pubitemid 351221040)
40. Noxafil (posaconazole) oral suspension [package insert]. Kenilworth, NJ: Schering-Plough Corp.; 2006.
41. B.D. Alexander J.R. Perfect J.S. Daly, et al. 2008 Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant Transplantation 86 791 796 10.1097/TP.0b013e3181837585 1:CAS:528:DC%2BD1cXhtFCrt7bP 18813103
42. G. Krishna A. Moton L. Ma, et al. 2009 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob Agents Chemother 53 958 966 10.1128/AAC.01034-08 1:CAS:528:DC%2BD1MXivF2lur4%3D 19075045
43. A.J. Ullmann J.H. Lipton D.H. Vesole, et al. 2007 Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease N Engl J Med 356 335 347 10.1056/NEJMoa061098 1:CAS:528:DC%2BD2sXhtVGktb4%3D 17251530 (Pubitemid 46148776)
44. O.A. Cornely J. Maertens D.J. Winston, et al. 2007 Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 348 359 10.1056/NEJMoa061094 1:CAS:528:DC%2BD2sXhtVGrsrw%3D 17251531 (Pubitemid 46148777)
45. E.G. Arathoon 2001 Clinical efficacy of echinocandin antifungals Curr Opin Infect Dis 14 685 691 1:CAS:528:DC%2BD38XktF2guw%3D%3D 11964885
46. J. Van Burik V. Ratanatharathorn D. Stepan, et al. 2004 Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis 39 1407 1416 10.1086/422312 15546073 (Pubitemid 39518200)
47. J. Tollemar K. Hockerstedt B.G. Ericzon, et al. 1995 Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study Transplantation 59 45 50 10.1097/00007890-199501150-00009 1:STN:280:DyaK2M7ktFeltw%3D%3D 7839427
48. T. Lorf F. Braun R. Ruchel, et al. 1999 Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation Mycoses 42 47 53 10.1046/j.1439-0507.1999.00266.x 1:CAS:528:DyaK1MXjvFels78%3D 10394848 (Pubitemid 29256326)
49. J.F. Castroagudin C. Ponton M. Bustamante, et al. 2005 Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients Transplant Proc 37 3965 3967 10.1016/j.transproceed.2005.10.043 1:CAS:528:DC%2BD28XksVCi 16386598 (Pubitemid 43015225)
50. N. Singh D.L. Paterson T. Gayowski, et al. 2001 Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy Transplantation 71 910 913 10.1097/00007890-200104150-00016 1:CAS:528:DC%2BD3MXjvVOhtrc%3D 11349726
51. H. Reichenspurner P. Gamberg M. Nitschke, et al. 1997 Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis Transplantation Proc 29 627 628 10.1016/S0041-1345(96)00363-6 1:CAS:528:DyaK2sXit12gsbw%3D (Pubitemid 27123555)
52. R.H. Drew A.E. Dodds D.K. Benjamin, et al. 2004 Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients Transplantation 77 232 237 10.1097/01.TP.0000101516.08327.A9 1:CAS:528:DC%2BD2cXmsFKmtQ%3D%3D 14742987 (Pubitemid 38155752)
53. M. Cruciani C. Mengoli M. Malena, et al. 2006 Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis Liver Transpl 12 850 858 10.1002/lt.20690 16628697
54. E.G. Playford A.C. Webster T.C. Sorrell, et al. 2006 Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients Eur J Clin Microbiol Infect Dis 25 549 561 10.1007/s10096-006-0182-3 1:CAS:528:DC%2BD28Xpt1Ontbk%3D 16912905 (Pubitemid 44379690)
55. Fungal infections. Am J Transplant 2004, 4(Suppl 10):110-134.
56. P.G. Pappas C.A. Kauffman D. Andes, et al. 2009 Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 503 535 10.1086/596757 1:CAS:528:DC%2BD1MXjslantLY%3D 19191635
57. S. Husain D. Zaldonis S. Kusne, et al. 2006 Variation in antifungal prophylaxis strategies in lung transplantation Transpl Infect Dis 8 213 218 10.1111/j.1399-3062.2006.00156.x 1:STN:280:DC%2BD28notlOnsQ%3D%3D 17116134 (Pubitemid 44787860)
58. E.J. Kwak S. Husain A. Obman, et al. 2004 Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients J Clin Microbiol 42 435 438 10.1128/JCM.42.1.435-438.2004 14715799 (Pubitemid 38082765)
59. S. Husain E.J. Kwak A. Obman, et al. 2004 Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients Am J Transplant 4 796 802 10.1111/j.1600-6143.2004.00415.x 15084177 (Pubitemid 38637580)
60. C.D. Pfeiffer J.P. Fine N. Safdar 2006 Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis Clin Infect Dis 42 1417 1427 10.1086/503427 1:CAS:528:DC%2BD28Xlt1Cqu74%3D 16619154
61. N. Singh M.M. Wagener T.V. Cacciarelli, et al. 2008 Antifungal management practices in liver transplant recipients Am J Transplant 8 426 431 1:STN:280:DC%2BD1c%2Fls1ansQ%3D%3D 18190655
62. N. Akamatsu Y. Sugawara J. Kaneko, et al. 2007 Preemptive treatment of fungal infection based on plasma (1 → 3) beta-D-glucan levels after liver transplantation Infection 35 346 351 10.1007/s15010-007-6240-7 1:CAS:528:DC%2BD2sXht1emu7fL 17885729 (Pubitemid 47502349)
63. C. Lumbreras V. Cuervas-Mons P. Jara, et al. 1996 Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation J Infect Dis 174 583 588 1:CAS:528:DyaK28XlvVOmsbw%3D 8769617
64. S.M. Palmer R.H. Drew J.D. Whitehouse, et al. 2001 Safety of aerosolized amphotericin B lipid complex in lung transplant recipients Transplantation 72 545 548 10.1097/00007890-200108150-00036 1:CAS:528:DC%2BD3MXmslyjtLk%3D 11502995
65. D.J. Winston A. Pakrasi R.W. Busuttil 1999 Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial Ann Intern Med 131 729 737 1:CAS:528:DyaK1MXnvFOgs78%3D 10577295